Oct. 24 at 4:43 PM
$APLS
The company was valued at 90+ dollar based on GA promise. However, in the last few quarters, the GA revenue stopped growing, which triggered big sell-off along with drama from extremely rare blindness triggered by injection.
If Q3, GA resumes growth, or if there is guidance of resuming growth from the management team, this will take off.
Keep in mind we have C3G/IC-MPGN launch ongoing, which is an very effective drug.
100K+ shares holding !